Alliance Pharma
Alliance Pharma plc, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and commercialisation of innovative healthcare products. Founded in 1998, the company has established a strong presence in various operational regions, including Europe and Asia, focusing on prescription medicines and over-the-counter products. With a diverse portfolio that includes unique formulations and niche therapeutic areas, Alliance Pharma is recognised for its commitment to quality and patient care. The company has achieved significant milestones, including strategic acquisitions that have bolstered its market position. Notably, Alliance Pharma has garnered accolades for its effective product range, which addresses unmet medical needs and enhances patient outcomes.
DitchCarbon Score
How does Alliance Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alliance Pharma's score of 45 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alliance Pharma's reported carbon emissions
In 2023, Alliance Pharma reported total carbon emissions of approximately 101,050 kg CO2e in Great Britain. This figure includes 45,580 kg CO2e from Scope 2 emissions, primarily from purchased electricity, and 55,470 kg CO2e from Scope 3 emissions, which encompass upstream transportation and distribution. Notably, there is no data available for Scope 1 emissions for this year. The company's global emissions for the same year totalled about 50,138,000 kg CO2e, with Scope 1 emissions at zero, Scope 2 emissions at 59,000 kg CO2e, and a significant 50,125,000 kg CO2e from Scope 3 emissions. This highlights the substantial impact of their supply chain and operational activities on overall emissions. Alliance Pharma has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. This context suggests that while the company is actively measuring its carbon footprint, it may still be in the early stages of developing a comprehensive strategy for emissions reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 7,000 | 00,000 | 0,000 | 0,000 | - |
| Scope 2 | 107,000 | 00,000 | 00,000 | 00,000 | 0,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alliance Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
